Snapshot Highlights
- Expert in Medical Oncology with extensive experience in cancer treatment.
- Specialized training from Marmara University Faculty of Medicine.
- Author of numerous publications in reputable oncology journals.
- Affiliated with prominent medical associations.
Dr. MEHMET TEOMETE
Professional Experience
Dr. Mehmet Teomete is a distinguished Medical Oncologist with a robust career dedicated to advancing cancer care. His professional journey began after completing his internal medicine specialization, where he honed his foundational medical knowledge. He has since served as a Medical Oncology Specialist at key institutions, including Trabzon Numune Training and Research Hospital and Erzurum Regional Training and Research Hospital. His tenure at Marmara University Faculty of Medicine for sub-branch specialization training provided him with in-depth expertise in the latest medical oncology treatments and research methodologies. He also has experience with the Acıbadem Health Group, further broadening his clinical exposure.
Education
- Medical Oncology Specialist, Marmara University Faculty of Medicine
- Internal Medicine Specialist, Haydarpasa Numune Training and Research Hospital
- Medical Doctor, Ankara University Faculty of Medicine
Memberships
- Medical Oncology Association
- Turkish Medical Association
Publications and Research
Dr. Teomete has made significant contributions to the field of medical oncology through his research and publications. He is an author on studies covering a wide spectrum of oncological topics, including the outcomes of chemotherapy in breast and lung cancers, the impact of treatment on patient weight, and specific case reports on rare oncological conditions. His work has been featured in esteemed journals and presented at major oncology conferences, demonstrating his commitment to evidence-based practice and the dissemination of medical knowledge. Notable publications include research on weight gain after adjuvant chemotherapy for breast cancer, the outcomes of metastatic colorectal cancer patients, and the impact of dose reductions for platinum compounds in non-small cell lung cancer.